文献速递胸部肿瘤

一项基于人群的研究描述荷兰EGFR突变IV期非小细胞肺癌患者的特征、生存及TKI治疗的影响

A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands.
PubMed 文献 · Eur J Cancer · 2022-03-03

研究基于荷兰癌症登记处2011-2018年确诊的31291例IV期非鳞非小细胞肺癌患者,其中7.0%登记为EGFR突变阳性。EGFR阳性患者中71%接受TKI治疗,多变量分析显示TKI使用与死亡风险降低相关(HR 0.45,95%CI 0.41-0.49)。全组中位总生存期随时间增加0.6个月,其中约33%归因于EGFR阳性患者的TKI治疗。

要点

  • EGFR突变在女性<40岁患者中患病率最高(16%)。
  • 中位总生存期从>65岁EGFR阴性组的3.5个月到<50岁EGFR阳性TKI治疗组的23.6个月。
  • TKI使用与死亡风险降低相关(HR 0.45,95%CI 0.41-0.49)。

核心结论

  • 在人群水平,TKI治疗对IV期非鳞非小细胞肺癌EGFR阳性患者结局有非常强的有益影响。
  • 全组多年总生存期的改善中约三分之一似乎归因于EGFR阳性患者的TKI治疗。

研究设计与样本

  • 基于荷兰癌症登记处的人群研究,纳入2011-2018年确诊的IV期非鳞非小细胞肺癌患者,共31291例。

主要发现

  • 全部患者中7.0%登记为EGFR阳性,女性<40岁患病率最高(16%)。
  • 中位总生存期从>65岁EGFR阴性组的3.5个月到<50岁EGFR阳性TKI治疗组的23.6个月。
  • 全组中位总生存期随时间增加0.6个月,其中33%归因于EGFR阳性患者的TKI治疗。
  • 女性<50岁患者中位总生存期几乎翻倍至12.4个月。
  • EGFR阳性患者中,多变量死亡风险与TKI使用关联最强(HR 0.45,95%CI 0.41-0.49);71%接受TKI治疗。

关键数值与推荐

  • 自2011年起,治疗指南建议对非小细胞肺癌中激活表皮生长因子受体(EGFR)突变(EGFR+)患者使用靶向治疗(酪氨酸激酶抑制剂,TKI)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Since 2011, treatment guidelines advise targeted therapy (tyrosine kinase inhibitor, TKI) for patients with activating epidermal growth factor receptor (EGFR) mutations (EGFR+) in non-small cell lung cancer (NSCLC). We describe characteristics, first line treatment and survival of patients diagnosed with EGFR+ NSCLC in a European population, focussing on age, gender and trends over time and compare to the whole group and EGFR-. METHODS: All patients with non-squamous NSCLC stage IV, diagnosed 2011-2018, were identified from the population-based Netherlands Cancer Registry (N = 31,291). RESULTS: Among all, 7.0% were registered to be EGFR+, with highest prevalence in females <40 years (16%). Median overall survival (OS) ranged from 3.5 months in the EGFR- group >65 years to 23.6 months in the EGFR+ group <50 years treated with TKI. Over time, OS for the whole group increased by 0.6 months, of which 33% due to TKI treatment in EGFR+. The increase was strongest in females <50 years, where median OS almost doubled to 12.4 months. In the EGFR+, multivariable hazard of death was most strongly associated with the use of TKI (HR 0.45(0.41-0.49)). Of the patients with EGFR+ this space need or not, 71% received TKI treatment. Being young reduced the hazard of death (HR 0.71(95%CI:0.59-0.85)) irrespective of treatment, while male gender increased the hazard of death (HR 1.22(95%CI:1.11-1.33)). CONCLUSION: At population level, TKI treatment in patients with non-squamous NSCLC stage IV EGFR+ has very strong beneficial effects on outcome. Of the improvement in OS that was made over the years for the whole group, about one third seems to be attributed to TKI treatment in EGFR+ patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ten Berge DMHJ, Aarts MJ, Groen HJM, et al. A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. Eur J Cancer. 2022. PMID: 35248841. doi:10.1016/j.ejca.2022.01.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。